Reset Health Taps GLP-1 Pioneer to Steer Obesity Care Revolution

LONDON, UK – February 11, 2026 – Digital health specialist Reset Health has appointed Pinder Sahota, the former head of Novo Nordisk UK, to its Advisory Board, a strategic move that underscores a significant shift in the management of chronic disease. Sahota, who was instrumental in the commercialisation of GLP-1 weight-loss medications in the UK, joins a rapidly strengthening team that recently welcomed former Deputy Chief Medical Officer for England, Professor Sir Jonathan Van-Tam.

The appointments signal Reset Health’s ambition to build a dominant position in the burgeoning ecosystem surrounding GLP-1 drugs like Wegovy and Mounjaro. By assembling a “dream team” of pharmaceutical industry leadership and public health authority, the company is positioning its technology-enabled care model as the essential support structure for patients navigating the complexities of these powerful new treatments.

Beyond the Pill: The New Frontier of Chronic Care

The advent of GLP-1 and GIP medications has been hailed as a revolutionary breakthrough in treating obesity and type 2 diabetes. However, their remarkable effectiveness has also exposed critical challenges in long-term healthcare delivery. Issues of high cost, intermittent supply shortages, and the potential for significant weight regain upon cessation have created an urgent need for comprehensive “wraparound” care that goes beyond the prescription pad.

This is the gap Reset Health aims to fill with its integrated platform, Roczen. The model combines its proprietary technology with a multidisciplinary clinical team of doctors, dietitians, and psychologists to provide holistic, long-term support. The program is explicitly designed to be used alongside anti-obesity medications, enhancing their effectiveness and promoting sustainable outcomes.

Evidence for this integrated approach is mounting. A retrospective service evaluation of the Roczen program demonstrated that patients achieved a clinically significant mean weight loss of 11% at 24 weeks. The study also reported marked improvements in eating behaviours, symptoms of depression, and overall health-related quality of life. The company's model is currently the subject of a £1.3 million research grant from the National Institute for Health and Care Research (NIHR) to evaluate its effectiveness and cost-efficiency within the NHS, signaling serious interest from the public health system.

“Reset Health’s approach recognises that obesity is a chronic condition that requires high-quality, multifaceted, long-term care, not a short-term, commodity approach to medication alone,” Sahota commented on his appointment. “I am delighted to support the team as they scale an integrated care model that combines clinical excellence with intelligent digital tools.”

A Strategic Assembly of Expertise

Pinder Sahota’s background makes him a uniquely valuable asset. As the former General Manager and Corporate Vice President at Novo Nordisk UK, he led the company during the meteoric rise of GLP-1s. His deep experience in the development and commercialisation of these exact drugs provides Reset Health with unparalleled insight into the pharmaceutical landscape it seeks to complement.

Beyond his corporate tenure at firms including GSK and AstraZeneca, Sahota has been a central figure in shaping UK and European health policy. His leadership roles as President of the Association of the British Pharmaceutical Industry (ABPI) and Chairman of the Confederation of Business Industry’s (CBI) Health Council have placed him at the heart of discussions on healthcare innovation and access.

His commercial and strategic acumen is now paired with the formidable public health credibility of Professor Sir Jonathan Van-Tam. The combination of a pharma industry heavyweight and a trusted government medical advisor creates a powerful brain trust for navigating the clinical, regulatory, and commercial hurdles of scaling a new model of care.

Oliver McGuinness, Chief Executive Officer at Reset Health, highlighted the strategic importance of the appointments. “His decades of experience as a pharmaceutical leader will be instrumental as we continue to build integrated, personalised models of care for people living with obesity and related chronic conditions,” he stated. “Alongside the recent addition of Sir Jonathan, Pinder’s appointment further bolsters our expert team as we work towards our mission of delivering meaningful and sustainable change for patients.”

Shifting Tides in Healthcare Innovation

Sahota’s move from a pharmaceutical giant to an advisory role at a digital health firm is emblematic of a broader talent migration shaping the future of healthcare. As the limitations of a purely pharmacological approach to chronic disease become clearer, industry leaders are increasingly recognizing that the next wave of innovation lies in the integration of technology, data, and behavioural science with medicine.

This trend signals a move away from a model focused solely on developing and selling medications towards creating holistic ecosystems that support patients throughout their entire health journey. Digital health companies like Reset Health are no longer seen as peripheral players but as essential partners in delivering value-based, sustainable healthcare.

The market they are entering is expanding rapidly. The global digital health for obesity sector was estimated at over $57 billion in 2024 and is projected to grow at a compound annual growth rate of over 20% in the UK. While the space includes established competitors like WW (WeightWatchers) and Noom, Reset Health’s clinically-led approach distinguishes it.

The company is regulated by the Care Quality Commission (CQC) and, crucially, its Roczen program has received a time-limited recommendation for use in the NHS from the National Institute for Health and Care Excellence (NICE) until March 2028, pending the generation of further evidence. This regulatory validation provides a significant competitive advantage over wellness-focused apps, positioning Roczen as a credible clinical service.

As the UK grapples with how to provide access to expensive GLP-1s—with an estimated 95% of current users paying privately—integrated digital models offer a potential solution. They present a pathway for health systems like the NHS to maximize the long-term value of these drugs, ensuring that investment in medication is supported by the lifestyle and behavioural changes necessary for lasting health improvement and potentially mitigating the high costs associated with lifelong dependency.